Chief Accounting Officer
Neurogene Inc. (NGNE)Equibles does not estimate personal net worth.
Get an email with a short summary when Neurogene Inc. publishes a filing, an earnings call transcript or a press release.
Get NGNE alertsSean Smith is recorded as CFO at Neurogene Inc. (NGNE) since March 31, 2023 and Chief Accounting Officer at Neurogene Inc. (NGNE) since March 2, 2022. Neurogene Inc. reported in an 8-K filed December 19, 2023 that Sean Smith was terminated as Interim Chief Financial Officer, effective December 18, 2023. Neurogene Inc. reported in an 8-K filed April 3, 2023 that Sean Smith was appointed Interim Chief Financial Officer, effective March 31, 2023. The proxy statement of Neurogene Inc. reports total compensation of $1,809,783 for Sean Smith in fiscal 2023, including a base salary of $384,102. Neurogene Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neurogene Inc. includes David J. Main (CEO), Donna M. Cochener (CEO), Rachel McMinn (CEO, Chairman and Board Member) and 7 others.
“Each of Donna M. Cochener, Neoleukin's Interim Chief Executive Officer and General Counsel, and Sean Smith, Neoleukin's Interim Chief Financial Officer, had their employment terminated at the Closing of the Merger, which terminations are considered to be without "cause" related to a change in control for purposes of their employment agreements with Neoleukin.”
“On April 3, 2023, the Board of Directors (the "Board") of Neoleukin Therapeutics, Inc. (the "Company") appointed (a) Donna M. Cochener as the Company's Interim Chief Executive Officer and designated her as the Company's principal executive officer and (b) Sean Smith as the Company's Interim Chief Financial Officer and designated him as the Company's principal financial officer (the "Executive Officer Appointments"), each effective as of March 31, 2023 ("the Effective Date").”
2023-03-31–present
2022-03-02–present
2023-03-31–2023-12-18
Start not stated–2023-12-18
NGNE
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2022-03-02–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Neurogene Inc. (NGNE) | Former Interim Chief Financial Officer | $384,102 | $1,809,783 |
